Nonetheless, the observed trend toward shorter OS in PD-L1-positive and CD8-high tumors supports the concept that a small immunologically active subset of liposarcomas may exhibit more aggressive clinical behavior and potential sensitivity to immune modulation. This evidence concerns the gene CD8A and liposarcoma.